HELP — CYBIN INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1833141 ·
Last close
$7.82
Market Cap
$484.72M
52W High
$8.45
52W Low
$3.76
ADV30
1,771,035
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -47,859,000 | -46,995,000 | 251,166,000 | 157,258,000 | 19,377,000 |
| Dec 2025 | 0 | — | -41,210,000 | -42,668,000 | 290,112,000 | 195,128,000 | 16,178,000 |
| Sep 2025 | 0 | — | -28,894,000 | -33,722,000 | 181,246,000 | 83,752,000 | 42,250,000 |
| Jun 2025 | 0 | — | -24,624,000 | -24,613,000 | 210,813,000 | 118,692,000 | 59,053,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-117,093,000
Investing CF
$-2,124,000
Financing CF
$219,389,000
CapEx
$-2,134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.87
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-342,540,000
Inventory
—
Receivables
$4,766,000
ST Investments
—
EBIT TTM
$-128,000,000
Pretax Income TTM
$-131,582,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -142,587,000 | -147,998,000 | 251,166,000 | 19,377,000 | — | -133,271,000 |
| Mar 2025 | 0 | -103,125,000 | -81,607,000 | 179,897,000 | 14,900,000 | — | -72,328,000 |
| Mar 2024 | 0 | -78,836,000 | -78,080,000 | 302,023,000 | 10,096,000 | — | -68,908,000 |
| Mar 2023 | 0 | -51,518,000 | -47,490,000 | 53,897,000 | 5,663,000 | — | -47,431,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.97
Max Pain — expiry 2026-08-21
max pain strike: $5.00 · spot: $7.82 · call oi: 5,992 · put oi: 2,983
Expected Move to 2026-08-21:
±$1.38
(17.58%) —
implied range
$6.45 –
$9.20
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLN | Silence Therapeutics plc | $495.49M | $10.49 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $497.61M | $25.11 | — |
| VREOF | Vireo Growth Inc. | $466.74M | $9.49 | — |
| QTTB | Q32 Bio Inc. | $465.83M | $15.68 | — |
| AQST | Aquestive Therapeutics, Inc. | $463.60M | $3.69 | — |
News headlines (Yahoo Finance, 1h cache)
Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions
2026-07-25 15:13 · Yahoo
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
2026-07-22 17:25 · Yahoo
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
2026-07-21 14:54 · Yahoo
Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million
2026-07-17 09:13 · Yahoo
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
2026-07-15 19:34 · Yahoo
Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?
2026-07-15 09:22 · Yahoo
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
2026-07-13 18:59 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-07-06 19:53 · Yahoo
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
2026-06-29 11:40 · Yahoo
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?
2026-06-26 22:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.